Compile Data Set for Download or QSAR
Report error Found 56 Enz. Inhib. hit(s) with all data for entry = 10839
TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333120(US10196393, Example 2 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0200nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK2(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM573151(US11453668, Example 8-15)
Affinity DataKi:  0.0300nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333120(US10196393, Example 2 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0400nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0500nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0500nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0500nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333145(US10196393, Example 8-23 | (S)-(3-(dimethylamino)-...)
Affinity DataKi:  0.0500nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0500nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM573140(US11453668, Example 8-4)
Affinity DataKi:  0.0600nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0600nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0600nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM573142(US11453668, Example 8-6)
Affinity DataKi:  0.0600nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431896(US10550118, Example 8-3 | US11453668, Example 8-3)
Affinity DataKi:  0.0600nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333144(US10196393, Example 8-22 | (S)-(3-(dimethylamino)a...)
Affinity DataKi:  0.0600nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431895(US10550118, Example 8-2 | US11453668, Example 8-2)
Affinity DataKi:  0.0600nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0600nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM573137(US11453668, Example 8-1)
Affinity DataKi:  0.0600nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0600nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.0600nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0800nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM573141(US11453668, Example 8-5)
Affinity DataKi:  0.0800nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM573151(US11453668, Example 8-15)
Affinity DataKi:  0.0800nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333136(US10196393, Example 8-14 | (S)-(5-ethyl-2-(6-(2-et...)
Affinity DataKi:  0.0800nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.0800nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.100nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.100nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.100nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK1(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.100nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333120(US10196393, Example 2 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.100nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333121(US10196393, Example 4 | (S)-(3-(dimethylamino)azet...)
Affinity DataKi:  0.130nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.130nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM573140(US11453668, Example 8-4)
Affinity DataKi:  0.130nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.160nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.160nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431896(US10550118, Example 8-3 | US11453668, Example 8-3)
Affinity DataKi:  0.160nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM573137(US11453668, Example 8-1)
Affinity DataKi:  0.180nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333145(US10196393, Example 8-23 | (S)-(3-(dimethylamino)-...)
Affinity DataKi:  0.200nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.200nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.200nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM573141(US11453668, Example 8-5)
Affinity DataKi:  0.200nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333136(US10196393, Example 8-14 | (S)-(5-ethyl-2-(6-(2-et...)
Affinity DataKi:  0.200nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.200nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM573142(US11453668, Example 8-6)
Affinity DataKi:  0.25nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM431895(US10550118, Example 8-2 | US11453668, Example 8-2)
Affinity DataKi:  0.25nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.25nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.25nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.280nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.320nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333122(US10196393, Example 8 | US10196393, Example 8-15 |...)
Affinity DataKi:  0.320nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase JAK3(Human)
Theravance Biopharma R&D Ip

US Patent
LigandPNGBDBM333144(US10196393, Example 8-22 | (S)-(3-(dimethylamino)a...)
Affinity DataKi:  0.320nMAssay Description:Assay 1: A panel of four LanthaScreen JAK biochemical assays (JAK1, 2, 3 and Tyk2) were carried in a common kinase reaction buffer (50 mM HEPES, pH 7...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/4/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 56 total ) | Next | Last >>
Jump to: